Form 8-K - Current report:
SEC Accession No. 0001104659-26-009495
Filing Date
2026-02-03
Accepted
2026-02-03 06:38:40
Documents
16
Period of Report
2026-02-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm264564d1_8k.htm   iXBRL 8-K 41995
2 EXHIBIT 99.1 tm264564d1_ex99-1.htm EX-99.1 577154
3 EXHIBIT 99.2 tm264564d1_ex99-2.htm EX-99.2 598631
8 GRAPHIC tm264564d1_ex99-1img001.jpg GRAPHIC 1703
  Complete submission text file 0001104659-26-009495.txt   1532939

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA mrk-20260203.xsd EX-101.SCH 4655
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mrk-20260203_def.xml EX-101.DEF 29174
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mrk-20260203_lab.xml EX-101.LAB 39688
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mrk-20260203_pre.xml EX-101.PRE 27658
18 EXTRACTED XBRL INSTANCE DOCUMENT tm264564d1_8k_htm.xml XML 10851
Mailing Address 126 EAST LINCOLN AVENUE P.O. BOX 2000 RAHWAY NJ 07065
Business Address 126 EAST LINCOLN AVENUE P.O. BOX 2000 RAHWAY NJ 07065 908-740-4000
Merck & Co., Inc. (Filer) CIK: 0000310158 (see all company filings)

EIN.: 221918501 | State of Incorp.: NJ | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-06571 | Film No.: 26590097
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)